epothilone D
information and resources from the National Cancer Institute
epothilone D
A natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility. epothilone D
A natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility.
|
|
|
|
news articles
Kosan Reports KOS-862 Interim Phase II Results in Patients With ... Dec 8, 2005
Yahoo! News (press release) The poster presentation #1087 "A Phase II Study of KOS-862 (Epothilone D) in Anthracycline and Taxane Pretreated Metastatic Breast Cancer: Updated Results ...
Kosan Announces Management Changes Dec 7, 2005
PharmaLive.com (press release), Kosan's most advanced compound, KOS-862 (Epothilone D), is in Phase II and Phase Ib clinical trials in breast cancer , and its follow-on compound, KOS-1584, is ...
Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination ... Dec 8, 2005
PR Newswire (press release), Kosan's most advanced compound, KOS-862 (Epothilone D), is in Phase II and Phase Ib clinical trials in breast cancer, and its follow-on compound, KOS-1584, is ...
Kosan Reports KOS-862 Interim Phase II Results in Patients With ... Dec 8, 2005
Yahoo! News (press release) The poster presentation #1087 "A Phase II Study of KOS-862 (Epothilone D) in Anthracycline and Taxane Pretreated Metastatic Breast Cancer: Updated Results ...
Kosan Announces Management Changes Dec 7, 2005
PharmaLive.com (press release), Kosan's most advanced compound, KOS-862 (Epothilone D), is in Phase II and Phase Ib clinical trials in breast cancer , and its follow-on compound, KOS-1584, is ...
Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination ... Dec 8, 2005
PR Newswire (press release), Kosan's most advanced compound, KOS-862 (Epothilone D), is in Phase II and Phase Ib clinical trials in breast cancer, and its follow-on compound, KOS-1584, is ...
|
|
